SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ONXX
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (778)6/5/2004 3:04:30 PM
From: Miljenko Zuanic  Read Replies (1) of 810
 
From WSJ:

"After 12 weeks, those 37 patients whose tumors had shrunk were unblinded, and given the drug with an open label. Another 38 patients whose tumors hadn't shrunk were continued in a randomized study, with half getting the drug and half getting a placebo.

Twelve weeks later, 59% of the patients in the randomized study had shown disease progression, compared with 12% for patients given the drug in the open-label study. There wasn't any significant further shrinkage of tumors after 12 weeks"

Majority of the open label sub-group are "stable disease".
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News